NS Support & resources

Comprehensive care coordination and support

At NS Support we are dedicated to being a committed partner to the families coping with Duchenne muscular dystrophy (DMD). We stand ready to provide optimal access support and resources—every step of the way—for patients, their caregivers, and healthcare professionals.

FOR HEALTHCARE PROFESSIONALS

  • Patient Start Form to enroll patients in NS Support
  • Rapid benefits investigation and verification
  • Reimbursement support
  • Streamlined product acquisition options

Support for physicians and their practices:

Patient Start Form Buy & Bill Order Form Patient Assistance Program Application Stay informed—sign up to receive additional information and updates >

FOR PATIENTS AND THEIR CAREGIVERS

  • Individualized, caring support and resources throughout the patient journey
  • Help with understanding insurance coverage for VILTEPSO
  • Co-pay Assistance Program—eligible patients may qualify for savings on their deductible, co-pay, and coinsurance for their medication costs for VILTEPSO*
  • Patient Assistance Program—help for uninsured patients in financial need

Support for patients and their caregivers:

Patient Authorization Form Patient Assistance Program Application Stay informed—sign up to receive additional information and updates >
Have questions? Call us today. 18336778778Have questions? Call us today. 18336778778

*Program covers the cost of the medication only and does not cover the costs to administer the infusion. See full Eligibility Requirements & Terms and Conditions on back of Affordability Options brochure.

Here are additional resources that you may find helpful

For Healthcare Providers:

VILTEPSO Overview

Summarizes the clinical evidence of the efficacy and safety of VILTEPSO and other product features

VILTEPSO Dosing and Administration

Provides you with information on how to prescribe, dose, and administer VILTEPSO as infusion therapy

NS Support Resource Guide

Provides information on initiating therapy and helping patients afford their treatment

VILTEPSO Infusion Quick Reference Guide

Provides information on how to appropriately dose and deliver VILTEPSO. It also contains a representative dosing chart as a guide for weekly infusions

For Patients and Caregivers:

VILTEPSO Overview

Explains the features of VILTEPSO in treating DMD, including efficacy and safety

Getting Started Guide

Answers common questions about what VILTEPSO does, how it works, and other concerns you may have

Infusion Overview Guide

Helps you better understand the weekly infusion process and address questions with your child in advance of their first session

Affordability Options

Provides an overview of the NS Support Co-Pay Assistance program, Patient Assistance Program (PAP) and Medicaid waiver programs

Understanding Government-Funded Health Insurance

Provides information about government-funded health insurance and financial assistance

DMD Foundation and Advocacy Groups

Includes a list of foundations and advocacy groups that may be able to provide assistance to DMD patients

Sign up to receive additional information and updates

Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

For more information about VILTEPSO, see full Prescribing Information.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.

For more information about VILTEPSO, see full Prescribing Information.